NCT06600321 - A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | Biotech Hunter

Enrollment

158

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

October 31, 2027

Conditions

Advanced Hepatocellular CarcinomaMetastatic Hepatocellular Carcinoma

Interventions

DRUG

ALN-BCAT

Administered by intravenous (IV) infusion

DRUG

Pembrolizumab

Administered by intravenous (IV) infusion

Trial Locations (19)

10029

RECRUITING

Clinical Trial Site, New York

10032

RECRUITING

Clinical Trial Site, New York

15232

RECRUITING

Clinical Trial Site, Pittsburgh

23298

RECRUITING

Clinical Trial Site, Richmond

32224

RECRUITING

Clinical Trial Site, Jacksonville

44106

RECRUITING

Clinical Trial Site, Cleveland

48109

RECRUITING

Clinical Trial Site, Ann Arbor

55905

RECRUITING

Clinical Trial Site, Rochester

60637

RECRUITING

Clinical Trial Site, Chicago

75390

RECRUITING

Clinical Trial Site, Dallas

77030

RECRUITING

Clinical Trial Site, Houston

78229

RECRUITING

Clinical Trial Site, San Antonio

85054

RECRUITING

Clinical Trial Site, Phoenix

90033

RECRUITING

Clinical Trial Site, Los Angeles

92093

RECRUITING

Clinical Trial Site, San Diego

Unknown

RECRUITING

Clinical Trial Site, Verona

RECRUITING

Clinical Trial Site, Busan

RECRUITING

Clinical Trial Site, Seongnam-si

RECRUITING

Clinical Trial Site, Seoul